Cavoatrial Thrombectomy without the Use of Cardiopulmonary Bypass for Abdominal Tumors. Our Experience and State of the Art

Vicente, Emilio; Quijano, Yolanda; Ielpo, Benedetto; Luca, Giuseppe Massimiliano De; Prestera, Antonio; Durán, Hipólito; Dı́az, Eduardo; Fabra, Isabel; Olivares, Sergio; Caruso, Riccardo

doi:10.1016/j.avsg.2015.01.021

Cited by 9 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total 53 articles were collected , including 5 (9.4%) retrospective studies [3,11,23,50,53], 4 (7.5%) case series [1,21,43,49], and 44 (83.0%) case reports [2, 4-10, 12-20, 22, 24-42, 44-48, 51, 52], with 187 patients involved. Even though cohort studies, case-control studies and case series are considered to form a hierarchy of increasing risk of bias, these studies reflected closely a routine practice or the usual setting where the intervention would be implemented.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular carcinoma with right atrial tumor thrombus: a meta-analysis

Yuan

Guo²

2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma with right atrial tumor thrombus is uncommon but with a dismal prognosis. Methods: By comprehensive retrieval of the pertinent literature published since 2000, 53 reports were collected with 187 patients recruited into this study. The quantitative data were expressed in mean±standard deviation with range and median values and were compared by independent samples t -test. The categorical variables were compared by Chi-square or Fisher exact test with continuity correction. Results: The survival rate of patients receiving transarterial chemoembolization was 33.3% and that of surgical patients was 41.9%. The survival time of patients with transarterial chemoembolization treatment was longer than that of surgical patients, but lack of a statistical significance. Conclusions: Even though advanced hepatocellular carcinoma with right atrial thrombus is an aggressive malignancy, the the present study showed that patient prognoses were improved and survival time was elongated with the advances of active treatments such as transarterial chemoembolization and surgical treatments. Active treatments are advised to patients with hepatocellular carcinoma with right atrial tumor thrombus in order to improve patients’ survival.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Hepatocellular carcinoma with right atrial tumor thrombus: a meta-analysis

Yuan

Guo²

2020

Preprint

View full text Add to dashboard Cite

show abstract

Section: Patient Characteristicsmentioning

confidence: 99%

“…One patient receiving a two-stage operation survived 6 months[38]. The surgical operation was performed under cardiopulmonary bypass (CPB) in 18 patients[2, 3, 18, 21, 28-30, 35, 38, 43, 45, 51, 52], under veno-venous bypass in 1 patient[25] and with total hepatic vascular exclusion (THVE) with no CPB in 15 patients[3,4,12,13,20,42,49,50].The operation time was 9.1±2.5 (range, 5.6-12.3; median 9.0) hours (n=12)[4, 7, 12, 25, 29-31, 35, 42, 45, 51, 52], the CPB time was 40.6±23.9 (range, 16-100; median, 38) min (n=9)[2,7,12,29,30,45,50,51,52], and the hepatic occlusion time was 29.4±26.3 (range, 10-87; median, 19) min (n=11)[4, 12, 13, 20, 25, 29-31, 42, 45, 52]. The total blood loss amount was 3.562,0±2,692.2 (range, 650-8,200; median, 2,692) mL (n=10)[7, 13, 25, 29-31, 35, 42, 51, 52].…”

mentioning

confidence: 99%

Hepatocellular carcinoma with right atrial tumor thrombus: a systematic review

Yuan¹,

Guo²

2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma with right atrial tumor thrombus is uncommon but with a dismal prognosis. Methods: By comprehensive literature retrieval of 2000–2019, 53 reports were obtained with 187 patients recruited into this study. The extracted data included patient characteristics, tumor characteristics, treatment, follow-up and outcomes. Statistical analyses applied were student t, Fisher exact and I2 tests. Patients were divided into 6 groups according to the treatment of choices: transarterial chemoembolization (TACE), surgery, radiotherapy, chemotherapy, intervention and supportive care. Results: The overall survival rate of this cohort was 40.8%. The survival rate of patients receiving TACE was 33.3% and that of surgical patients was 41.9%. The survival time of patients with TACE treatment was longer than surgical patients, but lack of statistical significance. Patients were under a follow-up of 15.7±16.6 (median 10) months. Patients receiving radiotherapy had under a longest follow-up among all groups. Intra- and/or extrahepatic recurrence of hepatocellular carcinoma was the major morbidity and also often causes of death. The mortality rates of patients with different treatments in a decremental sequence were supportive care >radiotherapy >surgery >TACE >intervention. No difference was noted in mortality between patients reported from case reports and those from non-case reports. Conclusions: Even though advanced hepatocellular carcinoma with right atrial thrombus is an aggressive malignancy, the present study showed that patients’ prognoses were improved and survival time elongated with active treatments such as TACE and surgery. Active treatments were thus advised to patients with hepatocellular carcinoma with right atrial tumor thrombus.

show abstract

“…One patient receiving a two-stage operation survived 6 months[38]. The surgical operation was performed under cardiopulmonary bypass (CPB) in 18 patients[2, 3, 18, 21, 28-30, 35, 38, 43, 45, 51, 52], under veno-venous bypass in 1 patient[25] and with total hepatic vascular exclusion (THVE) with 6 no CPB in 15 patients[3,4,12,13,20,42,49,50].The operation time was 9.1±2.5 (range, 5.6-12.3; median 9.0) hours (n=12)[4, 7, 12, 25, 29-31, 35, 42, 45, 51, 52], the CPB time was 40.6±23.9 (range, 16-100; median, 38) min (n=9)[2,7,12,29,30,45,50,51,52], and the hepatic occlusion time was 29.4±26.3 (range, 10-87; median, 19) min (n=11)[4, 12, 13, 20, 25, 29-31, 42, 45, 52]. The total blood loss amount was 3.562,0±2,692.2 (range, 650-8,200; median, 2,692) mL (n=10)[7, 13, 25, 29-31, 35, 42, 51, 52].…”

mentioning

confidence: 99%

Hepatocellular carcinoma with right atrial tumor thrombus: a systematic review

Yuan

Guo²

2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma with right atrial tumor thrombus is uncommon but with a dismal prognosis. Methods: By comprehensive retrieval of literature published between 2000 and 2019, 53 reports were obtained with 187 patients recruited into this study. The extracted data included patient characteristics, tumor characteristics, treatment, follow-up and outcomes. Statistical analyses applied were student t , Fisher exact and I 2 tests. Patients were devided into 6 groups according to treatment of choices: transarterial chemoembolization (TACE), surgery, radiotherapy, chemotherapy, interventional treatment and supportive care. Results: The overall survival rate of this cohort was 40.8%. The survival rate of patients receiving TACE was 33.3% and that of surgical patients was 41.9%. The survival time of patients with TACE was longer than surgical patients, but lack of a statistical significance. Patients had a follow-up of 15.7±16.6 (median 10) months. The patients receiving radiotherapy had the longest follow-up among all groups. Intra- and/or extrahepatic recurrence of hepatocellular carcinoma was the major mobidity. The mortality rates in a decremental sequence for patients receiving different treatments were supportive care >radiotherapy >surgery >TACE >interventional treatment. No difference was found in mortality between patients reported from case reports and those from non-case reports. Conclusions: Even though advanced hepatocellular carcinoma with right atrial thrombus is an aggressive malignancy, the the present study showed that patients’ prognosis was improved and survival time elongated with active treatments such as TACE and surgery. The present systematic review reveals improved outcomes with active treatments against conservative treatments.

show abstract

Cavoatrial Thrombectomy without the Use of Cardiopulmonary Bypass for Abdominal Tumors. Our Experience and State of the Art

Cited by 9 publications

References 4 publications

Hepatocellular carcinoma with right atrial tumor thrombus: a meta-analysis

Hepatocellular carcinoma with right atrial tumor thrombus: a meta-analysis

Hepatocellular carcinoma with right atrial tumor thrombus: a systematic review

Hepatocellular carcinoma with right atrial tumor thrombus: a systematic review

Contact Info

Product

Resources

About